Cytokinetics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Cytokinetics, Inc. (CYTK)

Q2 2012 Earnings Call

July 31, 2012, 4:30 p.m. ET


Sharon Barbari - EVP, Finance & CFO

Robert Blum - President & CEO

Andrew Wolff - SVP, Clinical Research and Development, & CMO

Fady I. Malik – SVP Research and Early Development


Ritu Baral – Canaccord Genuity

Charles Duncan - JMP Securities

Michael King – Rodman & Renshaw LLC

Simos Simeonidis – Cowen and Company

Chad Messer – Needham & Co.

George Zavoico – Mcnicoll, Lewis & Vlak



Good afternoon, and welcome Ladies and Gentlemen to the Cytokinets second quarter 2012 conference call. (Operator Instructions)

I will now turn the call over to Sharon Barbari, Cytokinets Executive Vice President of Finance and CFO. Please go ahead.

Sharon Barbari

Good afternoon, and thank you for joining the Cytokinets senior management team on this conference call today. Also present during this call are Robert Blum, our President and Chief Executive Officer, Dr. Andrew Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer, and Dr. Fady Malik, Senior Vice President of Research and Early Development.

Following the forward-looking statement disclaimer, Robert will provide a summary overview of the past quarter along with brief highlights on the advancement of clinical development pipeline including omecamtiv mecarbil and tirasemtiv, formerly referred to as CK2017357.

Andy will then provide details of recent progress in our skeletal muscle activator program directed to the potential treatment of ALS. And Fadi will provide details on recent progress in our cardiac muscle activator program directed to the potential treatment of heart failure.

If you liked this article you might like

Biotech Movers: Anika Up on Strong Analyst Ratings

Merger Buzz Drives Akorn to Top of Health Chart in April

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

These Stocks Are Trending Up With Monster Volume

7 Stocks Trending Up With Monster Volume